hotspot -WSS

hotspot

author：comprehensive 2025-09-06 04:42:04 - browse：288

Boxes of Ozempic photo illustration. -- health coverage from STAT — Mario Tama/Getty Images

LONDON — Novo Nordisk’s diabetes medication Ozempic cut the risk of patients developing advanced kidney disease or dying from kidney or heart complications, the company said Tuesday, adding to the evidence the wildly popular drug has broader health benefits for patients beyond addressing their diabetes.

Overall, Ozempic lowered the risk of progression of patients’ kidney disease and of related health events by 24% versus placebo, according to the topline results. The company, which will present full data from the study later this year, said it would file for an expanded approval of Ozempic based on the data in both the U.S. and Europe.

The positive announcement had been expected since October, when Novo announced it was ending the FLOW trial early because an interim data analysis showed the drug was surpassing the study’s goals. Still, the results provide an important data point for Novo both as its medicines face increasing competition and as it tries to get more insurers to cover its related obesity drug Wegovy.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

WSS

What affirmative action's end means to a medical student

The 10 drugs up first for Medicare price negotiation

What American doctors can learn from their Israeli counterparts

The biotech scorecard for Q3: 15 stock

UpToDate has a racism problem: Dr. Stanley Goldfarb

What American doctors can learn from their Israeli counterparts

hotspot

hotspot

explore

Medical records are filled with copy

A new House health package & hospitals’ new site

Affirmative action in medical school literally saved lives

Vertex cell therapy lets patients with type 1 diabetes stop insulin

Medicare details structure of new drug price negotiation program

How Robert F. Kennedy Jr. distorted vaccine science

Hepatitis C has a cure — but many Americans still lack access to it

'Screen and refer' systems are hurting patients

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Listen: Biogen's potential pivot, & Illumina's next chapter

leisure time

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

How generative AI is inspiring dreams of a health data revolution

House transparency, PBM reform bill gains bipartisan support

AstraZeneca lung cancer study comes in below expectations

Stem cell treatment guidelines are released by FDA

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

Wikipedia

explore

explore

focus